Rosiglitazone maleate (BRL 49653C, Rosiglitazone XR, Avandia)

Same activities as rosaglitazone but different formulation Antidiabetic, hypoglycemic agent. Potent and selective peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist. Potent insulin sensitizing agent binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. Ameliorates insulin resistance. Improves blood pressure and vascular function. Enhances proliferation of endogenous neural progenitor cells (NPCs). Anti-inflammatory compound. Has controversial therapeutic effects on the cardiovascular system.

Small volumes of Rosiglitazone maleate biochemical vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS6119134 is a biochemical targeting Rosiglitazone maleate. Also known as Rosiglitazone maleate (BRL 49653C, Rosiglitazone XR, Avandia).